Abstract
In this report, we present the 68Ga-DOTATATE PET/CT images of a patient with a metastatic neuroendocrine tumor with an intermediate-grade/Ki-67 index who had minimal somatostatin receptor positivity on baseline 68Ga-DOTATATE PET/CT but high-grade positivity on somatostatin receptor imaging (Krenning score, III–IV) on follow-up scans after chemotherapy. This redifferentiation-akin phenomenon in intermediate-grade neuroendocrine tumors after chemotherapy can have potential implications for the feasibility of peptide receptor radionuclide therapy in this group of patients in the later phase of their disease course.
Footnotes
Published online Feb. 28, 2020.